Search All Applications in Z-ARCHIVE-Cannabis
Application US20200046675
Published 2020-02-13
Cannabinoid Formulation Packaged In A Glass Vial For Pulmonary Delivery
A cannabinoid formulation comprising cannabinoid concentrate and beeswax, or a beeswax analogue, in a ratio of 30:1 to 40:1 by weight. Preferably the ratio is 35:1. The vaporizable formulation is packaged in a single use glass vial and used for pulmonary administration to a patient. The glass vial is made from borosilicate glass, has a cylindrical shape, an open end and no lid. The vial preferably has a uniform wall thickness of 0.02 inches. The formulation forms a wax seal at room temperature to eliminate any need for a lid. The formulation can be directly vaporized from the glass vial to eliminate transfer of the formulation to another container, to eliminate mess, to enable precise dosing, and to enable easy recycling and disposal of the vial after use.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1. A packaged cannabinoid formulation comprising a composition of cannabinoid concentrate and beeswax, wherein the ratio of the cannabinoid concentrate and the beeswax is in a range of 5:1 to 80:1;
the formulation is packaged in a cylindrical glass vial having a beeswax seal to enable the formulation to be vaporized directly from the cylindrical glass vial; and the glass vial has a coefficient of thermal expansion within the range of between 2×10−6 K−1 thru 5×10−6 K−1 at 20° C. to resist thermal shock and to enable the formulation to be vaporized directly from the cylindrical glass vial.
- 9. A vaporizable formulation comprising a composition of cannabinoid concentrate and a beeswax analogue, wherein the ratio of the cannabinoid concentrate and the beeswax analogue is in a range of 5:1 to 80:1; and
the beeswax analogue includes triacontanylpalmitate and cerotic acid, with the ratio of triacontanylpalmitate CH3(CH2)29O—CO—(CH2)14CH3 to cerotic acid CH3(CH2)24COOH being between 5:1 to 7:1, and the formulation is packaged in a cylindrical glass vial having a wax seal to enable the formulation to be vaporized directly from the cylindrical glass vial.
